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Three-dimensional cell cultures as a new tool  
in drug discovery
Abstract
Background and purpose: Producing of reliable information about 
pharmacological activity of new chemical entities is essential in early stages 
of drug discovery and development. There is a continuous need for improve-
ment of existing in vitro technologies, in order to get more accurate and more 
predictive biological data (and for compounds selection) in pre-clinical 
screening methods and models.
Materials and methods: Two-dimensional (2D) cell cultures, in com-
parison with original tissues, does not fully reproduce in vivo cell growth 
and differentiation. Therefore, significant efforts have been made toward 
the development of more realistic three-dimensional (3D) in vitro cell cul-
ture models that would better mimic tissue physiology.
Results: Two-dimensional (2D) cell cultures, in comparison with origi-
nal tissues, does not fully reproduce in vivo cell growth and differentiation. 
Therefore, significant efforts have been made toward the development of 
more realistic three-dimensional (3D) in vitro cell culture models that 
would better mimic tissue physiology. Basic concepts and advantages of 3D 
cell cultures, as well as different approaches in technologies that enable the 
cell growth in 3D will be presented here. Possible applications of 3D cell 
culture in drug discovery will be discussed, and example of formation of 
spherical growth of three different human breast cancer cells (MDA-
MB-231, SK-BR-3 and T-47D cells) in 3D format will be shown.
Conclusions: Although biological significance of obtained data from 2D 
and 3D cell cultures is still poorly understood, discrepancy of compunds 
activity illustrated importance of implementation 3D cell culture assays in 
early part of drug discovery process.
IntroductIon
The costs for successfully introduction a NCE (new chemical entity) drug compound to the market is between $800 million and $1,2 
billion, with an average duration of about 10 – 15 years. Expenses are 
even much higher in the case of late stage failure (or failure of already 
marketed drug) (1). Analyses of clinical trials reveal that about 67% of 
drug lead molecules fail in late clinical trials stages, most of them due 
to poor efficacy and safety issues. This high attrition rate indicate that 
current pre-clinical screening and in vitro models do not adequately 
provide critical information required for prediction of efficacy and 
safety issues, which remain the main reasons for drug failure (2). The 
ability of an assay to produce reliable information about tested NCEs is 
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covery and the development process could be the use of 
new technologies in pre-clinical screening and in vitro 
models, in order to ensure more accurate and more pre-
dictive data that would be the main guide through the 
go/no-go decision on NCE selection. Limitations of two-
dimensional (2D) cell cultures, related to the different cell 
shape, biochemical features, cellular environment and 
morphology of the cells (in comparison with original tis-
sue), is that they do not fully reproduce cell growth and 
differentiation of conditions in vivo. Therefore, in the last 
decade, significant efforts have been made towards the 
development of more realistic in vitro cell culture models 
which can be „near to in vivo” conditions. Three-dimen-
sional (3D) cell cultures are the product of such efforts 
due to the need to work with cellular models that better 
mimic tissue physiology.
Basic concepts and advantages of 3d 
cell cultures
The term three-dimensional (3D) cell culture is ap-
plied in relation to cell growth in a 3D environment, in 
some kind of matrix or on a scaffold with 3D structure. 
The term is used as opposite to the flat surface of conven-
tional two-dimensional (2D) cell cultures (3). Cell growth 
in 3D conditions is different and in many aspects advan-
tageous over conventional 2D culture conditions. In 2D 
culture conditions, cells need to adapt to a flat and rigid 
surface that can result in altered cell metabolism, bio-
chemical features, cell cycle kinetics, morphology, func-
tionality and cellular and physiological responses, in 
comparison to the native conditions that are present in 
organs (4). One of the key differences between these two 
growth conditions is the impact of the environment on 
the physical shape and geometry on the cell. It has been 
known that cell shape and contacts between cells influ-
ence the cytoskeleton which in turn can regulate gene and 
protein expression and influence on cell function. Cells 
grown in a 3D environment support their natural 3D 
physical shape, most often in a form of spheroids, which 
facilitates cell – cell regulatory mechanisms and signaling 
networks.
Spheroids are formed of cells with growth in three di-
mensions, which are composed of cells in various growth 
stages placed in different layers. Viable cells, most of them 
in the proliferating stage, are in the outer layer due to high 
exposition to the medium, where they form a proliferation 
zone (PZ) (5) (Figure 1). Cells in the core generate a qui-
escent or hypoxic zone (QZ), with necrotic or apoptotic 
cells in the centre (NZ). The proliferating rates and mor-
phology of 3D spheroids is dependent on cell types and 
the 3D model conditions in which the cells are cultured.
In addition to the homogeneous 3D cell cultures aris-
ing from single cell line, it is possible to prepare also three-
dimensional co-cultures with other cells and cellular 
components which naturally occur in their microenviron-
ment, and mimic complex organ-like structures which 
may be more clinically relevant. Use of heterogeneous 
cultures with several cell types is suitable for co-cultures 
and cell-extracellular matrix interactions discovery. Such 
microenvironment supports the growth, proliferation and 
migration of cells through a network of signals propa-
gated by interactions that include the extracellular matrix, 
other cells, growth factors, chemokines and cytokines.
Experimental tissue modeling has been very successful 
in mimicking structure and function of normal organs 
(like liver, for example), by using co-cultures of cells of 
different histological origin, such as hepatocytes and fi-
broblasts. In contrast, efforts at modeling solid tumors 
containing cells with various histologies and functions 
have remained sparse to date (5). Multicellular 3D culture 
systems containing more than one cell type and exhibit-
ing formation of a complex extracellular matrix represent 
a more physiologically relevant environment, yet provide 
a challenge and unmet need for in vitro pharmacological 
assay methods originally designed for measuring events 
from monolayers of cells.
3d cell culture technologies
There are many different approaches and technologies 
that enable the cell growth in 3D. A variety of new assay 
formulations, multiplexing and staining methods are de-
signed and validated for 3D cell culture models and mi-
crotissues, which are based on measuring of ATP for cell 
viability, DNA staining of dead cells, caspase markers of 
apoptosis, glutathione as marker of oxidative stress, or 
luciferase reporter expression, and further efforts are 
aimed in validation other assays and technologies using 
hanging drops, hydrogels, µ-fluidic assay chips and syn-
thetic scaffolds (6).
3D culture systems are classified as either scaffold-free 
or scaffold-based (natural or synthetic). Many companies 
provide scaffold-based 3D culture systems, with a huge 
variety of materials used in these technologies. More than 
100 types of matrices and scaffolds (organic and inor-
ganic) are currently in use. Some of these products are 
designed to improve the accuracy of in vitro assays in a 
routine and cost-effective manner and therefore have ap-
plication in laboratories on daily basis. Two different tech-
niques can be distinguished here: i) cell-seeding on an 
Figure 1: Spheroid cell growth composition; PZ proliferation zone, 
QZ quiescent or hypoxic zone, NZ necrotic zone.
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acellular 3D matrix and ii) dispersion of cells in a liquid 
hydrogel, followed by polymerization (7). One of most 
important characteristics of material used for 3D cell 
growth is their level of rigidity. The rigidity of matrix af-
fect extends to cell contraction. If the matrix is rigid, it is 
more difficult for the cells to contract, followed by stress 
fiber formation in cells and different cell function. Based 
on their rigidity, 3D materials can be classified into three 
categories: hydrogels, microporous „spongy” scaffolds and 
scaffold-free 3D spheroids or cellular aggregates (8).
Hydrogels possess high water content and cross-linked 
natural material (agarose, fibrin, collagen, laminin), 
which provide „soft” environments for cell growth. 3D 
materials based on hydrogels are used for a broad tissues 
types such as bone, cartilage and nervous. One of the very 
popular product of this group is MatrigelTM (9).
„Spongy” scaffolds materials are polystyrene, poly-L-
Lactide Acid or Poly (lactic–co–glycolic) acid (PLGA). 
The major advantages of these scaffolds are defined geom-
etry and fixed size of pores (10).
The generation of scaffold-free microtissue spheroids by 
gravity-enforced self-assembly in hanging drops, forced-
floating, or agitation-abased approaches has been used for 
decades, with particular versatility and interest in this type 
of the 3D culture system in the last decade (7).
Among others, scaffold-free 3D cell cultures produced 
with hanging drop configuration are one of the most con-
venient for in vitro screening usage. This method used a 
small aliquot of single cell suspension pipetted in the wells 
forming of drops and cells accumulate at the bottom of 
the drops, proliferate and form spheres. The hanging drop 
method is simple and has been reported to have a repro-
ducibility of almost 100% (11).
Such 3D spheroid culture techniques are today adapt-
ed and applicable for both basic research and high-
throughput screening (HTS). Design of 96-well or 384-
well microtitre plates used for scaffold-free 3D culture 
assays has become increasingly relevant for the pharma-
ceutical industry.
Applications of 3d cell culture in drug 
discovery
During the 1960s and 1970s, drug discovery was based 
largely on screening of chemical libraries of synthetic 
small molecules, natural products or extracts in either 
animal models, or organ systems, to identify substances 
that had a desirable therapeutic effect. Since the early 
1990s, the target-based drug discovery paradigm has be-
come the dominant approach in the pharmaceutical in-
dustry. This process is characterized by high-throughput 
screening of large compound libraries against isolated 
biological targets which are thought to be disease-related. 
Due to the suboptimal success of the target-based ap-
proach, a tendency towards screening in, so-called, phe-
notypic assays has reappeared in the last decade. Pheno-
type-based drug discovery generates molecules that 
produce biological effects in the biological system irre-
spective of their mode of action and the hit screening is 
performed with in vitro cell-based systems (phenotypic 
assays), and later with in vivo animal models that mimic 
specific aspects of disease (12). Today, phenotypic assays 
are connected with high content screening (HCS), a plat-
form that measures multiple parameters within the cell, 
and relationships between the analysed parameters. Fur-
thermore, 3D multicellular cultures have potential to 
improve phenotypic assays providing more relevant bio-
logical information in such a set up. Today, drug discov-
ery screening continues to complement HTS with HCS 
and 3D cell culture technology, which will become es-
sential for setup and development of more relevant in 
vitro assays (13).
Due to better correlation with in vivo conditions, 3D 
cultures have potential in the early phase of the drug dis-
covery process, especially in cell-based screening. The 
main applications are in research of stem cells, primary 
cells, human cell lines, cancer cells, growth factor release, 
and tumor xenografts. The most successfull improved 
types of such assays with 3D cultures are cell viability, 
proliferation, cell migration and signalling (14).
It was shown that 3D cell cultures have different gene 
and protein expression in comparison with 2D cell cul-
tures. Zschenker et al. compared gene expression levels in 
different cancer cell lines and their tissue origins and con-
cluded that more than 30% of genes have different expres-
sion level and this is a very important issue in target-ori-
ented screening (15). Also, proliferation rates of cells 
cultured in 3D conditions are lower in comparison to 
proliferation rates of same cells grown in 2D conditions. 
However, this depends on the 3D model and conditions 
of cell growth. Also, differences in cell viability were ob-
served. In short term cell cultures (up to 5 days) cell viabil-
ity is the same in 2D and in 3D growth conditions. In 
long term cell cultures cell viability in 3D conditions were 
slightly reduced probably due to the different exposure of 
cell area to the environment and dye uptake (16). To 
analyse early drug-drug interaction, human hepatocytes 
are the recommended in vitro assay system. The problem 
with such an assay is time limited Cytochrome P450 
(CYP) activity and stability. It was shown that 3D human 
hepatocyte cell cultures have advantage over 2D cell cul-
tures because viability of hepatocytes together with CYP 
activity is longer and more stable (17). The largest number 
of drug lead molecule failures is in the oncology field. One 
of the main reasons of high drug attrition rate in oncol-
ogy is that standard tools that cancer biologists use as 2D 
cell cultures in vitro have poor clinical predictive power 
(18). Conventional two-dimensional (2D) cell cultures are 
not able to completely describe malignant phenotypes 
that are related to tumorogenicity in vivo. In 2D culture 
conditions cells need to adapt to a flat and rigid surface 
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that can result in altered cell metabolism, functionality 
and pharmacological respond (4). Therefore, three-di-
mensional (3D) cell culture techniques have a valuable 
impact in the oncology field. Tumor spheroids are well 
established in basic cancer research and experimental 
therapeutics. Using these 3D cultures, significant progress 
has been made in understanding the regulation of inva-
sion and metastasis, of angiogenesis, and of cell cycle (5). 
Larger spheroids contain, along with other layers, areas of 
necrotic cells at the centre and are useful for influence of 
hypoxia in cancer research (Figure 1) (19). Evaluation of 
drug resistance and sensitivity generally showed that 
tested drugs showed different IC50 values in 3D cell cul-
ture assay in comparison with IC50 values obtained in 
2D assay (20).
Among other reasons, differences of 2D and 3D cell 
response can be also due to spatial organisation of surface 
receptors, cancer gene expression, and difference in cell 
stages, drug acceptability and pH gradient in spheroids. 
Nevertheless, results obtained in 3D cancer cells are more 
in line with in vivo models than results obtained in 2D, 
especially if patient-derived primary tumour cells are used 
rather that commercial cell lines (21).
Among various 3D methods, the hanging drop meth-
od is one of the best characterised models for 3D culture, 
with all its advantages and disadvantages (11). In our 
laboratory, we have excellent experience with 3D Bioma-
trix hanging drop plates (http://3dbiomatrix.com/, Figure 
2). They support production of 3D cell cultures of broad 
range of different cell lines, and enable produced 3D cul-
tures to be tested in a high-throughput manner (22). Also, 
because it is a scaffold free system, they eliminate the pos-
sibility of interaction of the NCE with scaffold material.
Among others, in such systems we tested amidino sub-
stituted benzimidazole and benzimidazo[1,2-a]quinoline 
derivatives (22 compounds) designed as a compounds 
with antitumor activity as a small platform for compari-
son of antitumor activity in 2D and 3D cell culture sys-
tems and for correlation with structure-activity relation-
Figure 2: 3D Biomatrix hanging drop plates used for 3D spheroid formation, treatment and analysis. Pictures taken from Perfecta3D® Hanging 
Drop Plates Protocols (https://3dbiomatrix.com/).
Figure 3: Formation of spherical growth of MDA-MB-231 cells in 3D format during period of 6 days (4-5x magnification, seeding density 5000 
cells/well). Pictures are taken in Fidelta Ltd., by using 3D Biomatrix hanging drop plates.
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ship (SAR). 3D hanging-drop cell culture method was 
applied on three human cancer breast cell lines (SK-BR-3, 
MDA-MB-231 and T-47D) and two pancreatic cancer 
cell lines (MIA PaCa-2 and PANC-1). As standard drugs 
we tested doxorubicin, docetaxel, vinorelbine and gemcit-
abine. All cell lines showed increased chemoresistance in 
3D cell growth to standard drugs and for some com-
pounds from our platform we have observed significant 
disagreement indicating that some prominent compounds 
can be discarded in the early phase of research, while a 
chance was given to compounds with false positive result 
(23). We concluded that, as well as in 2D assay, the shift 
in IC50 in a 3D cell culture models is not dependent only 
on the mode of action of the tested compounds, but it is 
Figure 5: Formation of spherical growth; T-47D in 3D format during period of 6 days (4-5x magnification, seeding density 5000 cells/well). 
Pictures are taken in Fidelta Ltd., by using 3D Biomatrix hanging drop plates.
Figure 4: Formation of spherical growth of SK-BR-3 cells in 3D format during period of 6 days (4-5x magnification, seeding density 5000 cells/
well). Pictures are taken in Fidelta Ltd., by using 3D Biomatrix hanging drop plates.
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also affected by the cell line sensitivity and (in case of 3D 
cultures) spheroid stability, and cell line growth have an 
impact on the cell line sensitivity. Examples of day-to-day 
formation of 3D spherical growth for different tumor cell 
lines, by using Perfecta3D hanging drop plates which are 
easy-to-use multi-well plates that facilitate uniform spher-
oid formation, are presented on Figures 3, 4, and 5, where 
optimal timing needed for ideal spheroid formation could 
be very nicely recognized for every particular cell line.
Limitations of 3d cell cultures
Despite the above mentioned advantages and tremen-
dous progress made to adjust 3D culture technologies for 
pharmaceutical applications, there are still some limita-
tions in 3D cell cultures methods, which still fail to pro-
vide relevant, standardized and validated 3D cell/tissue 
models. The ideal method for 3D cell culture is not yet 
optimised due to lack of a quantifiable entity of biomark-
ers of three dimensionality. That means that 3D cell cul-
tures should have description of at least of two factors: 
spatial that describes dimensions, structure and spheres 
compactibility; and some biochemical biomarkers which 
would suggest composition of the microenviroment that 
ensure physiologically relevant cell response. There are 
also limitations that are specific for method type as vari-
ability of cell size, viability and number of cells per well, 
nonequal exposure of cells in well to drug activity, time 
consuming plate preparation, lack of specific equipment, 
etc. For scaffold-based cell culture systems, reproducibil-
ity between different batches is still unsatisfactory, and 
potential interactions of screening compounds with the 
scaffold, which is influenced also with the compound 
properties (hydrophilic or hydrophobic). In summary, the 
benefits of 3D cell culture system in terms of biological 
relevance (especially for pharmaceutical applications) is 
obvious, but there are still many hurdles and unmet 
needs, which prevent universal standardization of 3D 
culture systems for drug development (7)
concLusIon
The on-going trend is moving toward creating new 
therapies which should be more effective, reliable and safe, 
but on the other hand they should be less costly. How-
ever, credibility of the pharmaceutical industry and aca-
demic researchers continue to erode in advocating their 
traditional pipeline development strategies yielding only 
modest drug innovation successes. New trends in indus-
trial drug development should use innovative and more 
improved new technologies in the drug development pro-
cess. Those novel trends in experimentation with cells 
include attempts to obtain and maintain functional dif-
ferentiation of human cells similar to those in vivo. Pri-
mary tissues (healthy or diseased) or isolated early passage 
primary cells are cultured in so-called ‘ex vivo’ cultures. 
Significant efforts are made to co-culture primary cells 
with the hope of at least partially simulating the in vivo 
environment. On the other hand, established cell lines 
can be cultured on specially manufactured growth sur-
faces (hollow fibre bioreactor, cellular multilayers on po-
rous membranes), matrices (matrix embedded culture) 
and in controlled heterologous monolayer systems, as well 
as 3D cultures (multicellular spheroids), moving away 
from „flat biology” (24). The data obtained are integrated 
and analysed using systems biology and biomapping ap-
proaches. All in all, the pendulum is moving from his-
torically highly reductionist approaches in in vitro biology 
towards mimicry of the in vitro and in vivo environment. 
Stem cells and associated in vitro organ formation, dedi-
cated to in vitro compound testing, as well as research on 
their potential for therapeutic application, are creating a 
seed for the fast growth of regenerative medicine.
All these novel approaches will definitely aid the better 
understanding of multi-cellular in vivo biology and will 
contribute significantly towards improvement of the in-
herently high attrition rate of drug discovery (25, 26). 
Therefore, use of traditional 2D cell cultures and persis-
tence of them as cell screening for NCE toxicity and ef-
ficacy is questionable. Cells grown in a 3D model have 
proven to be more physiologically relevant: they have a 
longer lifespan, their growth is undisturbed (without 
regular trypsinisations), and expressed genotype as well 
as phenotype are more relevant to in vivo conditions. 
Based on all the above mentioned differences between 
traditional 2D cell cultures and 3D spheroid cultures, 
three-dimensional cell cultures in a form of multicellular 
spheroids should become mandatory test systems in ther-
apeutic screening programs.
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